ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Salah Mabrouk Khallaf, Elsayed Mostafa Ali, Ahmed M. Maklad, Mohamed Medhat Samir, Anwar Tawfik Amin, Muhammad Abbas El-Masry, Mona M. Sayed, Dalia Osama
Background: Treatment of frail elderly patients with pancreatic cancer is still a major problem due to intolerance to standard chemotherapy doses. Aim: This study aims to compare the low-dose gemcitabine over 6 hours (LD6H) to the standard gemcitabine protoco…
Junyi Shi, Ai Shen, Tong Mou, Zhongjun Wu
The prognosis of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is very poor although sorafenib is recommended as the first-line treatment. Therefore, an effective treatment regime is needed for treating HCC with PVTT. This review sum…
Aya Hossam Mansy, Alsiagy A. Salama, Fatma Gharib Khair-Allah, Lamiss Mohamed Abd El-Aziz
Background: The sixth most prevalent cancer in the world is head and neck squamous cell carcinoma (HNSCC). In multiple combinations, surgery, radiation and chemotherapy are used in HNC control. As radiation-induced sali vary gland damage and xerostomia is one…
Ashraf Zedain, Hosny Badrawy, Mayada Fawzy, Dina Ismail Abd El Razik, Sanaa Saber, Abeer Ibrahim
Background: Micro RNA 21 (miRNA - 21) is overexpressed in numerous solid types of tumor s , indicating that its biology is relevant to numerous types of cancer. However, in Colorectal Cancer (CRC) there is a lot of studie s confirmed its use as diagnostic mar…
Nagy Samy Gobran, Mohammed Reda Kelany, Mohammed Abdallah Fathy
Background: Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer-related deaths in the world. The treatment of stage III CRC consists of surgery followed by adjuvant chemotherapy with either single agent capecitabine…
Ilan Morad, Hanan Itzhaki
One of the main reasons for developing cancer drug-resistance is the ability of cancer cells to adopt mutations that help them fight the treatments. Cancer cells are very mutagenic. This makes the population of cancer cells in any tumor, or any other cancer c…
Eleana Hatzidaki, Maria Papadimitriou, Ioannis Papasotiriou
In recent years the use of natural supplements in order to prevent, treat or delay recurrence of cancer or reduce chemotherapy toxicity has attracted much attention. One such supplement is Capsol-T which consists of de - caffeinated green tea and chili pepper…
Yasutake Uchima, Naoki Aomatsu, Gen Tsujio, Takehiko Iwauchi, Shinji Matsutani, Hiroto Tanaka, Hironari Miyamoto, Takuma Okada, Shigeaki Kurihara, Toshiki Hirakawa, Keiichiro Hirata, Junya Morimoto, Shigehito Yamagata, Kazuhiro Takeuchi
Background: The SOFT study was a phase III trial designed to validate the non-inferiority of S-1 and oxaliplatin (SOX) plus bevacizumab to mFOLFOX6 plus bevacizumab in terms of PFS in patients with metastatic colorectal cancer (mCRC) who had not previously re…
Azza M. Adel, Dalia Abdelghani
Background : Breast cancer is defined according to molecular subtypes. Each molecular subtype defines different disease behavior and requires different tr eatment. The different molecular subtypes have different risk factors and diffe rent distribution across…
Andreia Cruz, Sarah Lopes, Maria Leitão, Sónia Carvalho, Olga Sousa, Manuela Machado
Retrorectal cystic hamartomas are rare congenital lesions that can undergo malignant transformation, and adenocarcinoma is the most frequently described histological type. The authors describe a case of a 53-year-old female patient with a localized well-diffe…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).